trial

Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

NCTId NCT04807530
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 160 (estimated)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2026-12-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
160 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2020-11-12
Primary completion
2026-12-30
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
TMS

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Karuna Subramaniam, PhDPrincipal Investigator

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
160
Phase
NA
Primary Completion Date
2026-12-30
Status
RECRUITING
relationships
The graph out of here
drug
TMS
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Karuna Subramaniam, PhD
person